Alnylam错过了2025年Q4收入估计数,造成净亏损,尽管收入增长强劲,2026年指导,其股票却下跌。 Alnylam missed Q4 2025 earnings estimates, posted a net loss, and saw its stock drop despite strong revenue growth and 2026 guidance.

Alnylam制药公司报告,2025年的Q4净损失为每股0.82美元,缺少估计数,收入为11亿美元,低于预期,尽管年同比上升了84.9%,其驱动因素是AMVUTTRA为ATTR-CM强劲销售。 Alnylam Pharmaceuticals reported a Q4 2025 net loss of $0.82 per share, missing estimates, and revenue of $1.10 billion, below expectations, though up 84.9% year-over-year, driven by strong sales of AMVUTTRA for ATTR-CM. 该公司实现了全年公认会计原则的盈利能力,并重申了2026年的49-53亿美元收入准则。 The company achieved full-year GAAP profitability and reiterated 2026 revenue guidance of $4.9–$5.3 billion. 它引入了长期的“Alnylam 2030”目标,包括25%以上的收入增长和~30%的非一般公认的会计原则利润率。 It introduced long-term “Alnylam 2030” goals, including over 25% revenue growth and ~30% non-GAAP margins. 尽管特许使用费和定价造成近期差幅压力,但该公司启动了三个新的第三阶段试验和一个新的制造平台。 Despite near-term margin pressure from royalties and pricing, the company launched three new Phase 3 trials and a new manufacturing platform. 内幕销售股位跌至306.53美元,分析师维持“机动购买”评级。 Stock dipped to $306.53 amid insider sales, with analysts maintaining a “Moderate Buy” rating.